Esperance alliance with MD Anderson Cancer Center could accelerate use of anti-cancer drug

    Baton Rouge-based Esperance Pharmaceuticals Inc. has entered into a strategic alliance agreement with MD Anderson Cancer Center to accelerate the clinical development of its lead anti-cancer drug EP-1…


    Already a subscriber? Sign in.

    We are glad you enjoy reading Business Report.

    Continue reading this story and get ACCESS to all our content from any device with a subscription now.

    • Get access to more than a decade of story archives.
    • Get access to our searchable data center of TOP LISTS.
    • Get exclusive content only available to INSIDERS.